drugset / Trial / NCT02688790

Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection

NCT02688790

Phase 1 Terminated 8 enrolled AbbVie
RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the Pharmacokinetic (PK) profile of a single intravenous (IV) infusion dose of dalbavancin, and to evaluate the safety and tolerability of a single dalbavancin IV infusion.

Timeline

Start
2016-04-01
Primary completion
2019-04-03
Completion
2019-04-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalbavancin Other / unclassified 22.5 mg/kg Intravenous